Han‐Joon Kim, Sarah Mason, Thomas Foltynie, Sophie Winder‐Rhodes, Roger A. Barker, Caroline H. Williams‐Gray November 17, 2019

Abstract

Background

Long‐term population‐representative data on motor fluctuations and levodopa‐induced dyskinesias in Parkinson’s disease is lacking.

Methods

The Cambridgeshire Parkinson’s Incidence from GP to Neurologist (CamPaIGN) cohort comprises incident PD cases followed for up to 13 years (n = 141). Cumulative incidence of motor fluctuations and levodopa‐induced dyskinesias and risk factors were assessed using Kaplan‐Meyer and Cox regression analyses.… Read More...

Jonathan Zurawski November 17, 2019

Multiple Sclerosis Journal, Ahead of Print.
Background:Meningeal inflammation may contribute to gray matter (GM) involvement in multiple sclerosis (MS) and is proposed to manifest as magnetic resonance imaging (MRI) leptomeningeal enhancement (LME).Objective:To investigate how LME relates to GM lesions in relapsing-remitting multiple sclerosis (RRMS) at 7T.Methods:A total of 30 RRMS subjects (age (mean ± standard deviation (SD)): 44.0 ± 11.3 years, 93% on disease-modifying treatment) and 15 controls underwent gadolinium-enhanced three-dimensional (3D) MP2RAGE (magnetization-prepared 2 rapid gradient-echo) and fluid-attenuated inversion recovery (FLAIR) MRI.… Read More...

admin November 17, 2019

Abstract

Background

Long‐term population‐representative data on motor fluctuations and levodopa‐induced dyskinesias in Parkinson’s disease is lacking.

Methods

The Cambridgeshire Parkinson’s Incidence from GP to Neurologist (CamPaIGN) cohort comprises incident PD cases followed for up to 13 years (n = 141). Cumulative incidence of motor fluctuations and levodopa‐induced dyskinesias and risk factors were assessed using Kaplan‐Meyer and Cox regression analyses.… Read More...

Nadya Pyatigorskaya, Lydia Yahia‐Cherif, Rahul Gaurav, Claire Ewenczyk, Cecile Gallea, Romain Valabregue, Fatma Gargouri, Benoit Magnin, Bertrand Degos, Emmanuel Roze, Eric Bardinet, Cyril Poupon, Isabelle Arnulf, Marie Vidailhet, Stéphane Lehericy November 17, 2019

Abstract

Background

Progressive supranuclear palsy (PSP) is a neurodegenerative clinically heterogeneous disorder, formal diagnosis being based on postmortem histological brain examination.

Objective

We aimed to perform a precise in vivo staging of neurodegeneration in PSP using quantitative multimodal MRI. The ability of MRI biomarkers to differentiate PSP from PD was also evaluated.… Read More...

Nadya Pyatigorskaya, Lydia Yahia‐Cherif, Rahul Gaurav, Claire Ewenczyk, Cecile Gallea, Romain Valabregue, Fatma Gargouri, Benoit Magnin, Bertrand Degos, Emmanuel Roze, Eric Bardinet, Cyril Poupon, Isabelle Arnulf, Marie Vidailhet, Stéphane Lehericy November 17, 2019

Abstract

Background

Progressive supranuclear palsy (PSP) is a neurodegenerative clinically heterogeneous disorder, formal diagnosis being based on postmortem histological brain examination.

Objective

We aimed to perform a precise in vivo staging of neurodegeneration in PSP using quantitative multimodal MRI. The ability of MRI biomarkers to differentiate PSP from PD was also evaluated.… Read More...

Andoird App
Loading...